Combining fisetin and ionizing radiation suppresses the growth of mammalian colorectal cancers in xenograft tumor models

• Published in: Oncology letters 2016-12, Vol.12 (6), p.4975-4982
• Main Authors: Leu, Jyh-Der, Wang, Bo-Shen, Chiu, Shu-Jun, Chang, Chun-Yuan, Chen, Chien-Chih, Chen, Fu-Du, Avirmed, Shiirevnyamba, Lee, Yi-Jang
• Format: Article
• Language: English
• Subjects: Analysis; Apoptosis; Cancer; Cancer therapies; Care and treatment; Cell cycle; Cell growth; Chemotherapy; Colorectal cancer; fisetin; Flavonoids; Health aspects; Immunoglobulins; Ionizing radiation; Laboratory animals; Oncology; Polyphenols; Protein expression; Proteins; Radiation therapy; Radiotherapy; securin; Studies; Tumors; xenograft tumor model; Xenotransplantation
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2016.5345

Fisetin (3,7,3′,4′-tetrahydroxyflavone), which belongs to the flavonoid group of polyphenols and is found in a wide range of plants, has been reported to exhibit a number of biological activities in human cancer cells, including antioxidant, anti-inflammatory, antiangiogenic, anti-invasive and antiproliferative effects. Although previous in vitro studies have shown that fisetin treatment increases the apoptotic rate and enhances the radiosensitivity of human colorectal cancer cells, the in vivo effects of fisetin on tumor growth remain unclear. In the present study a murine xenograft tumor model was employed to investigate the therapeutic effects of fisetin in combination with radiation on CT-26 colon cancer cells and human HCT116 colorectal cancer cells. This revealed that intratumoral injection of fisetin significantly suppressed the growth of CT-26 tumors compared with the untreated control group, but had little effect on the growth of HCT116 tumors. However, fisetin in combination with 2-Gy radiation enhanced tumor suppressor activity in murine colon and human colorectal xenograft tumors, as compared with 2-Gy fractionated radiation administered alone for 5 days and fisetin alone. Interestingly, fisetin downregulated the expression of the oncoprotein securin in a p53-independent manner. However, securin-null HCT116 tumors showed only moderate sensitivity to fisetin treatment, and the combination of fisetin and radiation did not significantly suppress securin-null HCT116 tumor growth compared with normal HCT116 tumors. Therefore, the role of securin in mediating the effect of fisetin on colorectal cancer growth warrants further investigation. In conclusion, the results of the current study provide important preclinical data for evaluating the efficacy of fisetin and radiation combination treatment as an adjuvant chemoradiotherapy for human colorectal cancers.